Open an account

Longeveron

LGVN · NASDAQ

$1.50+$0.11 (+7.91%)TodayMarket closed ·
Prev close $1.39

LGVN analyst rating

BuyConsensus of 2 analysts over the last 12 months. 50% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold1
  • Underperform0
  • Sell0

12-month price target · 4 analysts

Average $42.97 (+2764.5% upside)

Low
$4.29
Now
$1.50
High
$84.00

Upgrades and downgrades

The latest rating actions, newest first

LGVN analyst upgrades, downgrades and rating actions
FirmDateActionRating
Maxim GroupMay 11, 2026DowngradeBuy → Hold
HC Wainwright & Co.May 4, 2026MaintainsBuy

The case for and against

Updated Feb 2, 2026

Bull case

Longeveron Inc is positioned favorably due to its investigational product, Lomecel-B, which has demonstrated significant safety and efficacy in improving survival rates in patients with Hypoplastic Left Heart Syndrome, achieving a remarkable 100% five-year transplant-free survival rate compared to the historical standard of care at 80%. The ongoing Phase 2b ELPIS II study has the potential to further validate Lomecel-B's effectiveness, and a successful outcome could lead to FDA approval, a critical milestone given the current lack of advanced therapies for HLHS patients. Financially, a revised discounted cash flow analysis indicates a substantial upside potential, suggesting a valuation of $3 per share, significantly exceeding its current share price, thereby reflecting strong investor interest and expectations for future growth.

Bear case

Longeveron Inc has faced a significant decline in its stock value, dropping approximately 56% year-to-date, due in part to concerns over unexpected safety signals during the clinical development of its investigational product, Lomecel-B, particularly in patients with Hypoplastic Left Heart Syndrome. Additionally, there are substantial risks associated with the ongoing ELPIS II study, which may fail to produce positive efficacy results, as well as potential delays in securing necessary funding to advance clinical development and regulatory approval processes. These issues are compounded by uncertainties surrounding market penetration and possible dilution risks that could hinder the company's growth prospects and investor confidence.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.